A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria * Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period. * Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib. * Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS. Exclusion Criteria * Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason. * Participants must not have any evidence of active Tuberculosis (TB). * Other protocol-defined Inclusion/Exclusion criteria apply.
About the study
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
What is being tested
- BMS-986165 (drug)
Sponsor: Bristol-Myers Squibb · Participants: 35 · Started: Feb 24, 2026
Contact the study team
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · Phone: 855-907-3286
Official record on ClinicalTrials.gov — NCT06875960
Locations in the U.S.
| New York | New York University School Of Medicine, New York |
| Oklahoma | Oklahoma Medical Research Foundation, Oklahoma City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.